United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 8,000 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHRGet Rating) CEO Martine A. Rothblatt sold 8,000 shares of the firm’s stock in a transaction on Monday, November 21st. The stock was sold at an average price of $266.93, for a total transaction of $2,135,440.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $34,700.90. The sale was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Trading Up 0.4 %

Shares of NASDAQ:UTHR opened at $265.59 on Tuesday. United Therapeutics Co. has a fifty-two week low of $158.38 and a fifty-two week high of $270.61. The company has a market cap of $12.10 billion, a PE ratio of 18.07, a P/E/G ratio of 1.77 and a beta of 0.59. The company’s 50-day moving average price is $228.55 and its 200 day moving average price is $224.37. The company has a quick ratio of 9.39, a current ratio of 9.68 and a debt-to-equity ratio of 0.18.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Cookson Peirce & Co. Inc. raised its position in shares of United Therapeutics by 0.8% during the 3rd quarter. Cookson Peirce & Co. Inc. now owns 5,196 shares of the biotechnology company’s stock worth $1,088,000 after buying an additional 43 shares in the last quarter. Formidable Asset Management LLC raised its position in shares of United Therapeutics by 2.2% during the 3rd quarter. Formidable Asset Management LLC now owns 2,330 shares of the biotechnology company’s stock worth $491,000 after buying an additional 51 shares in the last quarter. Fifth Third Bancorp raised its position in shares of United Therapeutics by 2.2% during the 2nd quarter. Fifth Third Bancorp now owns 2,426 shares of the biotechnology company’s stock worth $572,000 after buying an additional 53 shares in the last quarter. Hancock Whitney Corp raised its position in shares of United Therapeutics by 0.4% during the 3rd quarter. Hancock Whitney Corp now owns 12,183 shares of the biotechnology company’s stock worth $2,550,000 after buying an additional 53 shares in the last quarter. Finally, M&T Bank Corp raised its position in shares of United Therapeutics by 4.3% during the 1st quarter. M&T Bank Corp now owns 1,328 shares of the biotechnology company’s stock worth $239,000 after buying an additional 55 shares in the last quarter. 95.57% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on UTHR. Bank of America restated an “underperform” rating on shares of United Therapeutics in a research report on Tuesday, September 20th. HC Wainwright raised their price target on shares of United Therapeutics from $255.00 to $300.00 and gave the stock a “buy” rating in a research report on Thursday, November 3rd. Oppenheimer raised their price target on shares of United Therapeutics from $325.00 to $375.00 and gave the stock an “outperform” rating in a research report on Thursday, November 3rd. Wedbush raised their price target on shares of United Therapeutics from $250.00 to $305.00 in a research report on Thursday, November 3rd. Finally, Morgan Stanley lifted their price objective on shares of United Therapeutics from $288.00 to $322.00 and gave the company an “overweight” rating in a research report on Thursday, November 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $282.75.

United Therapeutics Company Profile

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Articles

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.